Pharma stocks surge as Budget 2026 unveils Rs 10,000 crore ‘Biopharma Shakti’ push

Pharma stocks rally sharply

Pharma stocks rallied sharply after Finance Minister Nirmala Sitharaman announced a major push to position India as a global biopharma manufacturing hub in the Union Budget 2026. The government unveiled the “Biopharma Shakti” initiative, with an outlay of Rs 10,000 crore over the next five years, aimed at strengthening domestic manufacturing of biologics and biosimilars.

The ‘BioPharma Shakti’, with an outlay of Rs 10,000 crore over the next five years, will support domestic production of biologics and biosimilars and position India as a global biopharma manufacturing hub. "I propose Bio Pharma Shakti with a proposal of Rs 10,000 crore for next 5 years,” the finance minister said.

The programme is expected to boost capacity creation, reduce import dependence, and improve India’s competitiveness in high-value biopharmaceutical segments.

Biocon was the top gainer at 11.15 a.m., rising 2.5 percent to quote Rs 375.90 per share. Piramal Pharma, Sun Pharma, and Torrent Pharma also traded with strong gains.

Market participants cheered the announcement, betting that the policy support will translate into stronger growth prospects for domestic pharma companies, particularly those with exposure to complex generics, biologics, and contract manufacturing.

As part of the healthcare push, Sitharaman proposed the BioPharma Strategy for Health Advancement through Knowledge, Technology, and Innovation, stating that it will strengthen India’s digital healthcare ecosystem.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.